



**National  
University  
of Rwanda**



**FACULTY OF MEDICINE**  
**MEDICAL STUDENTS' ASSOCIATION OF RWANDA**  
**STANDING COMMITTEE ON RESEARCH EXCHANGE**

---

**EPIDEMIOLOGICAL ASPECTS,  
ETIOLOGIES AND CLINICAL OUTCOME OF  
MENINGITIS IN HIV-INFECTED PATIENTS  
IN THE SOUTHERN PROVINCE OF  
RWANDA**

**Supervisor**

Dr Ruth M. ROTTBECK  
Neurologist, CHUB

**By**

KANYAMAHANGA Herman (Doc II)  
NSHIMIYIMANA Jules Fidèle (Doc II)

November 2007

## **ACKNOWLEDGEMENTS**

We would like to acknowledge the help of all those who assisted with this study through its many stages. The Association of African Universities (AAU) was especially helpful for their financial support.

Our special, heartfelt thanks to Dr Ruth M. ROTTBECK, you believed in us and accepted to mentor this good study. Despite your ever busy schedule, you gave us time, listened to us, advised till the realization of this work.

Special thanks to Pr. Dr NSANZE Herbert, Dean of Faculty of Medicine at NUR and Pr. Dr WANE Justin, AAU HIV/AIDS Project Officer, for their invaluable support.

We are blessed with many supportive friends and colleagues who have made special contributions to this work in their own ways.

## ABBREVIATIONS

|                 |  |
|-----------------|--|
| AAU             | Association of African Universities                        |
| AIDS            | Acquired Immune Deficiency Syndrome                        |
| CD <sub>4</sub> | Cluster of Differentiation                                 |
| CHUB            | Centre Hospitalier Universitaire de Butare                 |
| CHUK            | Centre Hospitalier Universitaire de Kigali                 |
| CMV             | Cytomegalovirus  |
| CNS             | Central Nervous System                                     |
| CSF             | Cerebro-spinal Fluid                                       |
| EBV             | Epstein Barr Virus   |
| HAART           | Highly Active Anti Retroviral Treatment                    |
| HIV             | Human Immune-deficiency Virus                              |
| HSV             | Herpes Simplex Virus                                       |
| NUR             | National University of Rwanda                              |
| PNILT           | Programme Nationale Intégré de Lutte contre la Tuberculose |
| TB              | Tuberculosis   |
| VDRL            | Venereal Disease Research Laboratory                       |
| WBC             | White Blood Cell   |

**CONTENTS**

|  |     |
|--|-----|
| ACKNOWLEDGEMENTS .....   | i   |
| ABBREVIATIONS .....  | ii  |
| CONTENTS .....   | iii |
| List of Tables .....   | v   |
| List of Charts .....   | v   |
| ABSTRACT .....   | vi  |
| I. Introduction .....  | 1   |
| II. BACKGROUND .....   | 2   |
| II.1. Physiopathology of Meningitis .....                              | 2   |
| II.1.1. Meninges .....   | 2   |
| II.1.2. Cerebrospinal fluid .....                                      | 2   |
| II.1.3. Pathogenesis .....   | 2   |
| II.2. Meningites in HIV infected adults .....                          | 3   |
| II.2.1. Main Etiologic germs for HIV/AIDS infection in adults.....     | 3   |
| II.2.2. Diagnostic methods.....  | 4   |
| II.2.3. Treatment.....   | 6   |
| III. METHODS.....  | 8   |
| III.1. Study design.....   | 8   |
| III.2 Ethical issues .....   | 8   |
| III.2. Area of the study .....   | 8   |
| III.3. Inclusion criteria .....  | 8   |
| III.4 Methodology of data collection .....                             | 8   |
| III.4.1 Collected data .....   | 8   |
| III.4.2 Data management.....   | 8   |
| III.5. Limitations .....   | 9   |
| IV. RESULTS .....  | 10  |
| IV.1 Description of the study population.....                          | 10  |
| IV.2 Socio-demographic profile of the study population .....           | 11  |
| IV.2.1 Origin.....   | 11  |
| IV.2.2 Age of the patients.....  | 11  |
| IV.2.3 Sex .....   | 12  |
| IV.2.4 Occupation .....  | 12  |
| IV.2.5 Marital status .....  | 13  |
| IV.2.6 Distribution of patients according on the period of study ..... | 14  |
| IV.3 Past medical history and Clinical aspects .....                   | 14  |
| IV.3.1 Past medical history .....                                      | 14  |

|   |    |
|---|----|
| IV.3.2 Clinical signs of meningitis in HIV-positive patients.....                                       | 15 |
| IV.3.3 Clinical manifestation of HIV/AIDS.....  | 16 |
| IV.3.4 Distribution of patients according to type of meningitis and CSF biochemical parameters<br>..... | 16 |
| IV.4 Outcome .....  | 18 |
| IV.5 Duration of stay in hospital .....   | 18 |
| IV.6 Prognostic.....  | 19 |
| V. DISCUSSIONS AND COMMENTS.....  | 20 |
| V.1 General view.....   | 20 |
| V.2 Socio-demographic profile of study population.....  | 20 |
| V.2.1 Origin of the patients .....  | 20 |
| V.2.2 Types of meningitis according to sex and age .....  | 20 |
| V.3 Etiologies of meningitis in HIV-positive patients.....  | 20 |
| V.4 Clinical aspects .....  | 21 |
| V.4.1. Clinical signs .....   | 21 |
| V.4.2 Past medical history.....   | 21 |
| V.5 Para clinic aspects .....   | 21 |
| V.6 Outcome in the hospital.....  | 22 |
| V.7. Prognostic factors.....  | 22 |
| VI. Conclusions and recommendations.....  | 23 |
| VI.1. Conclusions.....  | 23 |
| VI.2 Recommendations.....   | 24 |
| REFERENCES .....  | 25 |
| ANNEXES .....   | 26 |

## List of Tables

|  |    |
|--|----|
| TABLE 1: Predominantly lymphocytic meningitis .....  | 3  |
| TABLE 2: Etiologies of purulent meningitis.....  | 4  |
| TABLE 3: Comparison of CSF founding between Purulent and lymphocytic meningitis .....                      | 5  |
| TABLE 4: Management of predominantly lymphocytic meningitis .....  | 6  |
| TABLE 5: First line treatment of purulent meningitis .....   | 7  |
| Table 6: Comparison of meningitis and other pathologies in HIV+ positive patients in our study .....       | 10 |
| Table 7: Distribution of HIV patients hospitalized from 2001-2006.....                                     | 10 |
| Table 8: Types of meningitis .....   | 10 |
| Table 9: Origin of the patients.....   | 11 |
| Table 10: Distribution of HIV-meningitis co-infection by age group .....                                   | 12 |
| Table 11: Distribution of HIV-meningitis co-infection by sex .....   | 12 |
| Table 12: Distribution of HIV-meningitis co-infection by occupation .....                                  | 13 |
| Table 13: Repartition of HIV-meningitis co-infection by marital status .....                               | 13 |
| Table 14: Distribution of patients by year of hospital stay .....  | 14 |
| Table 15: Distribution of patients according to past morbid history and type of meningitis .....           | 14 |
| Table 16: Distribution of patients according to clinical signs and types of meningitis .....               | 15 |
| Table 17: Distribution of patients according to clinical manifestation of HIV and type of meningitis ..... | 16 |
| Table 18: Distribution according to the macroscopic aspects of CSF.....                                    | 16 |
| Table 19: Distribution of patients according to CSF glucose and type of meningitis.....                    | 17 |
| Table 20: Distribution of patients according to LCR proteins and type of meningitis .....                  | 17 |
| Table 21: Distribution of patients by CSF WBC count and type of meningitis .....                           | 17 |
| Table 22: Outcome after treatment according to the type of meningitis.....                                 | 18 |
| Table 23: Duration of hospitalization according to the type of meningitis.....                             | 18 |
| Table 24: Outcome according to the duration of treatment .....   | 19 |

## List of Charts

|   |    |
|---|----|
| Graph 1: types of meningitis observed .....                                   | 11 |
| Graph 2: Neck stiffness in HIV-positive patients affected by meningitis ..... | 15 |

## ABSTRACT

**Background:** Meningitis associated with HIV/AIDS has an important impact considering morbidity and mortality. In Rwanda yet no study has been conducted on epidemiological aspects, etiologies and clinical outcome of meningitis in HIV-infected patients in the southern province of Rwanda.

**Objectives:** this study was conducted to assess the epidemiological aspects, the etiologies and the clinical outcome of meningitis in HIV-positive patients.

**Methods:** Data were collected onto paper questionnaires about socio demographic and clinical data; then entered onto the computerized questionnaires driven by epi-data software. The final analysis was done with the help of SPSS (version 14.0). As threshold for the statistical tests we used a p value of <0.05

**Results:** Between 2001 and 2006, in a total number of 495 hospitalized HIV-positive patients, 86 cases (17.37%) of meningitis have been recorded. Three types of meningitis were observed: Cryptococcus (64%), tuberculous (24.4%) and bacterial (11.6%). Headache, high fever, neck stiffness, Kernig sign and vomiting are the most frequent signs in all types of meningitis seen in this study. Laboratory diagnostic of Cryptococcus meningitis is easier and highly specific using Indian ink ( $p=0.000$ ), the diagnosis of tuberculous meningitis is presumptive while bacterial meningitis is mainly based on CSF biological findings. The CSF protein were more useful to differentiate between the types of meningitis ( $p=0.000$ ). Among 55 patients with Cryptococcus meningitis 40% died. 28.6% of TB meningitis patients died. For bacterial meningitis patients, 60% died. The chances to recover are increased in patients who survive the first 14 days of treatment ( $p=0.001$ ).

**Conclusion:** This study shows that meningitis still has a high prevalence in HIV-positive patients, with Cryptococcus neoformans being the leading cause.

## I. Introduction

Promising developments have been seen in recent years in global efforts to address the AIDS epidemic. But on the other hand the number of people living with HIV continues to grow as does the number of deaths due to AIDS. A total of 39.5 million people were living with HIV in 2006 (2.6 million more than in 2004). Sub Saharian Africa continues to bear the brunt of the global epidemic: Two thirds (63%) of HIV-infected persons live in Sub Saharian Africa with its epicentre in southern Africa. One third (32%) of HIV-infected persons live in southern Africa and 34% of all death occur there.

Rwanda is also concerned by this epidemic disease. Of a total population of 8 440 820 in 2005, the estimated number of people living with HIV/AIDS was 190 000. The number of deaths due to AIDS was 21 000.

Frequently HIV doesn't kill directly. Instead, it weakens the body's ability to fight disease. Infections which are rarely seen in those with normal immune systems are life-threatening to those with HIV. Many opportunistic infections cause different severe affections such as several pulmonary diseases, chronic diarrhea, neurological defects, and different bacterial, parasitic and fungal infections. Among those affections meningitis associated with HIV/AIDS has an important impact considering morbidity and mortality.

Different forms of meningitis are associated with HIV infection. They can be classified according to the etiologic agent as cryptococcal, tuberculous, syphilitic, Listeria species, etc. Others are lymphomatous or aseptic. Fungi are common in HIV-positive patients but HIV predisposes to several viral and bacterial infections that can result in meningitis.

In 1996, BERGMAN and KARSTAED (1) showed at Bargwanath Hospital that 37.3% of all HIV infected patients have meningitis. ELI SILBER et al. (5) revealed a co-infection of 66.7% at Goldfields West Hospital in 1999 in the same country. In a prospective study done in Zimbabwe, a meningitis and HIV/AIDS co-infection of 80% was documented by HAKIM et al. (9) in the patients hospitalised in internal medicine department during 2000.

So far two studies (CHUK Department of internal medicine) have been performed on this co-infection in Rwanda. The first was done by BOGAERTS et al. (8) between 1983 and 1992 showing a Cryptococcus meningitis co-infection rate of 19%. The second was done by NDUWIMANA in 2002 and 79.3% of all meningitis cases had the co-infection Meningitis and HIV/AIDS.

As there was no previous similar study done in the southern region we have been motivated to conduct this study with the following objectives:

- Identify epidemiological aspects of meningitis in HIV-Infected patients: prevalence and mortality among patients hospitalized in CHUB
- Identify the frequent etiologies of meningitis in HIV-Infected patients
- Identify the mortality rate of meningitis in HIV-Infected patients
- Identify the prognostic factors of death in affected patients



## **II. BACKGROUND**

### **II.1. Physiopathology of Meningitis**

#### **II.1.1. Meninges**

Meninges are three layers of membranes that surround the brain and spinal cord. The outer layer, dura mater, is tough white fibrous connective tissue. The middle layer of meninges is arachnoid, a thin layer resembling a cobweb with numerous threadlike strands attaching it to the innermost layer. The space under the arachnoid, the subarachnoid space, is filled with cerebrospinal fluid and contains blood vessels. Pia mater is the innermost layer of meninges. This thin, delicate membrane is tightly bound to the surface of the brain and spinal cord and cannot be dissected away without damaging the surface.

#### **II.1.2. Cerebrospinal fluid**

Cerebrospinal fluid (CSF) is an uncolored fluid with density around 1.005 mg/ml that flows within the ventricles of the brain, the central canal of the spinal cord and out to the subarachnoid spaces surrounding the brain and spinal cord, effectively floating these two structures. The normal protein level is 20 to 30mg/100ml. The lymphocytes are less than 5 per ml. The pH value is 7.3. It serves as a medium for the transfer of substances between the blood and the nervous tissues as well as a liquid buffer, absorbing mechanical shocks to the brain or the cord. Most of CSF is provided by the choroid plexuses that reside in lateral, third and fourth ventricles. In adults, the volume of is 125 to 150 ml. It is in continuous formation, circulation and absorption.

#### **II.1.3. Pathogenesis**

##### *II.1.3.1. Definition*

Meningitis can be defined as inflammation of the subarachnoidal space and meningitis without direct involvement of brain parenchyma (Hammer and Collony 1992 (6)). If the brain itself is infected the condition is called encephalitis whereas a combination of both is called meningio-encephalitis.

##### *II.1.3.2. Physiopathology*

The most common causative organisms of community-acquired bacterial meningitis are *S. pneumoniae* and *N. meningitidis*. Frequently the patient suffered pneumonia, an acute otitis media or an acute sinusitis before the onset of meningitis. Less commonly *L. monocytogenes*, gram negative cocci, enteric gram negative bacilli and *H. influenzae* are responsible.

*N. meningitidis* colonizes the nasopharynx even in many healthy people the risk of meningitis depends on the virulence of the bacteria and the immunity of the host.

They are attached to the epithelial mucosa before they pass to general infection by haematogenous invasion. Because of decreased defense of immune system, they will pass over the blood-brain barrier and will proliferate in CSF. This liquid has no sufficient mechanisms of defense and there will be a secretion of inflammation mediators such as cytokine, interleukins 1 and 6, prostaglandins, and so on. These mediators will cause meninges inflammation, and then white blood cells and proteins

will appear in the CSF. The vasogenic oedema of brain is due to an increase of blood-brain barrier permeability combined with effects resulting in secretion of cytokines and leucocytes degranulation; while the cytotoxic oedema of the brain is due to cytotoxic products from micro-organisms. All these effects will increase intracranial pressure.

## II.2. Meningites in HIV infected adults

Although HIV-positive individuals are at increased risk of certain types of meningitis, typically cryptococcal and tuberculous, evidence suggests that they are also more likely than the general population to develop community-acquired bacterial or viral meningitis. An early form of aseptic, HIV-associated meningitis develops within days to weeks after HIV infection. It appears as a mononucleosis-like illness and is rarely associated with encephalitis. Meningitides due to *Cryptococcus*, coccidioidomycosis, histoplasmosis, or other fungal infections are AIDS-defining events and occur typically with very low CD4<sup>+</sup> lymphocyte counts.

In Zimbabwe, HAKIM et al. (9) showed a decrease of purulent meningitis in adult hospitalised patients and an increase of TB and *Cryptococcus* meningitis. This was attributed to a rapid growth of this epidemic infection to HIV/AIDS. In this study meningitis was one of the most severe opportunistic affection in HIV-infected patients.

### II.2.1. Main Etiologic germs for HIV/AIDS infection in adults

TABLE 1: Predominantly lymphocytic meningitis

| Virus                      | Bacteria      | Parasites       | Fungi          |
|----------------------------|---------------|-----------------|----------------|
| <b>Enterovirus:</b>        | Tuberculosis  | Toxoplasmosis   | Cryptococcosis |
| - Coxsackie A and B virus  | Syphilis      | Trypanosomiasis | Candidosis     |
| - ECHO virus               | Listeriosis   |                 |                |
| - Poliovirus               | Bucellosis    |                 |                |
| <b>Paramyxovirus</b>       | Leptospirosis |                 |                |
| <b>Herpes virus:</b>       | Rickettsiosis |                 |                |
| - HSV1, HSV2               |               |                 |                |
| - HSV6                     |               |                 |                |
| - Zona and Varicella virus |               |                 |                |
| - CMV                      |               |                 |                |
| - EBV                      |               |                 |                |
| <b>HIV</b>                 |               |                 |                |
| <b>Adenovirus</b>          |               |                 |                |
| <b>Arena virus</b>         |               |                 |                |
| <b>Arbovirus</b>           |               |                 |                |

Source: Nduwimana JMV, *Méningites associées au VIH/SIDA chez l'adulte au CHK : Aspects diagnostic, thérapeutique, et évolutif. A propos de 82 cas.*

## B) Purulent meningitis

TABLE 2: Etiologies of purulent meningitis

| Form and Gram         | Germ   |
|-----------------------|--|
| Gram negative cocci   | <i>Neisseria meningitidis</i>  |
| Gram positive cocci   | <i>Streptococcus pneumoniae</i><br><i>Streptococcus agalactiae B</i><br><i>Staphylococcus epidermidis</i><br><i>Staphylococcus aureus</i>  |
| Gram negative bacilli | <i>Escherichia coli</i><br>Salmonella<br>Pseudomonas aeruginosa<br>Acinetobacter<br>Enterobacter<br>Serratia<br>Proteus<br><i>Klebsiella pneumoniae</i><br><i>Haemophilus influenza</i><br>Aeromonas |
| Gram positive bacilli | <i>Listeria monocytogenes</i><br>Corynebacteria<br>Bacillus<br>Actinomyces   |

### II.2.2. Diagnostic methods

#### A) Clinic

A number of symptoms clinically allow to suspect meningitis:

- Symptoms from inflammation of the meninges: a severe headache that won't go away, fever and neck stiffness; were mostly associated with signs from irritation of the meninges such as Kernig and Brudzinski sign
- Signs from increased intracranial pressure: vomiting, bradycardia, arterial hypertension.
- Behavior troubles : trouble of consciousness as agitation, somnolence and even coma

## B) Para clinic

TABLE 3: Comparison of CSF founding between Purulent and lymphocytic meningitis

|  | <b>Purulent meningitis</b>  | <b>Lymphocytic</b>   |
|--|---|--|
| <b>Macroscopic aspects</b>             | Purulent or xanthochromic CSF   | Clear CSF  |
| <b>Opening pressure</b>                | High (>180 mmH <sub>2</sub> O)  | Normal or slightly increased                                     |
| <b>Leukocytes</b>                      | Increased (frequently >1000 WBC/mm <sup>3</sup> with neutrophilic predominance) | High (10-2000 WBC/mm <sup>3</sup> with lymphocytic predominance) |
| <b>Ratio CSF glucose/blood glucose</b> | <0.3  | >0.6   |
| <b>CSF protein</b>                     | Increased (frequently >100mg/dl)  | Normal or slightly increased                                     |
| <b>Gram coloration</b>                 | Positive or negative (50%-80%)  | -  |
| <b>Culture</b>                         | Frequently positive   | Negative   |

## Other investigations:

- Funduscopy to investigate Bouchut tubercules, to search for signs of CMV-infection of the retina, papilledema,...
- IDR tuberculin test
- Chest X-ray to exclude pulmonary tuberculosis and pneumonia of other origin
- VDRL if neuro-syphilis is suspected
- Hemoculture can show sometimes the causal germs.
- Soluble antigens (meningococcus, pneumococcus, Cryptococcus,...)
- Sedimentation rate, hemogram and WBC to differentiate between bacterial and viral infection
- Blood smear for malaria

## II.2.3.Treatment

### A. Predominantly lymphocytic meningitis

TABLE 4: Management of predominantly lymphocytic meningitis

| Type of meningitis  | Drugs   | Dosage   | Treatment duration   |
|---|---|--|--|
| <b>TB meningitis</b>  | 2RHZ7E7/7-10RH3   | R: 10mg/kg/d<br>H: 5mg/kg/d<br>Z: 30mg/kg/d<br>E: 20mg/kg/d  | 9 – 12 months <sup>1</sup>   |
| <b>Cryptococcus meningitis</b>                                | Acute Therapy <sup>2</sup> :<br>- Amphotericine<br>(±Flucytosine)<br><br>Therapeutic serial<br>lumbar punctures<br><br>Premedication:<br><br>- Hydrocortisone<br><br>- Aspegic<br><br>Maintenance Therapy <sup>3</sup><br><br>Fluconazole | Amphotericine B:<br>0.7-1 mg/kg/d<br><br>Flucytosine:<br>75-100 mg/kg/d<br><br>100mg/dose<br><br>1g/dose | Amphotericine B±<br>Flucytosine for at<br>least 2 weeks<br>followed by<br>Fluconazole 400<br>mg/day per os to<br>complete a 10 weeks<br>course<br><br>Lifetime |
| <b>Syphilitic meningitis</b>                                  | Penicillin G or<br>Ceftriaxone  | Penicillin G: 200000-<br>400000 UI/kg/d<br>Ceftriaxone: 1-2g/j   | 10 days  |
| <b>H. capsulatum meningitis</b>                               | Amphotericine B or<br>Ketoconazole or   | Amphotericine B:<br>0.5-1 mg/kg/d<br><br>Ketoconazole and<br>Itraconazole: 400 –<br>600 mg/d             | ± 3 months   |
| <b>Viral meningitis</b>                                       | Symptomatic   | -  | Until recovery   |
| <b>Particular case:<br/>Herpetic meningo<br/>encephalitis</b> | Acyclovir   | 10-15mg/kg/dose  | 14-21 days   |

<sup>1</sup> National protocol according to PNILT suggests a treatment duration of 6 months

<sup>2</sup> Administered every day

<sup>3</sup> Administered every day for Fluconazole, once or twice for Amphotericine B

## B. Purulent meningitis

TABLE 5: First line treatment of purulent meningitis

|                           | Frequent germs                        | Antibiotics of choice                     | Dosage   |
|---------------------------|---------------------------------------|---|--|
| <b>Unknown gram stain</b> | -                                     | Ceftriaxone or<br>Cefotaxime ± Ampicillin | Ceftriaxone:2g/12h<br>Cefotaxime:2g/6h<br>Ampicillin:2g/4h |
| <b>Gram + cocci</b>       | S. pneumonia<br>S. aureus             | Ceftriaxone or<br>Cefotaxime+Vancomycine  | Vancomycine:1-2g/12h                                       |
| <b>Gram- cocci</b>        | L. monocytogenes                      | Ampicillin or Gentamicine                 | Gentamicine:1.5-<br>2.5mg/kg/d                             |
| <b>Gram- bacillus</b>     | N. meningitis                         | Chloramphenicol or<br>PenicillinG         | Chloramphenicol:1g/8h<br>PenicillinG:4MUl/4h               |
|                           | H. influenza<br>E. coli<br>Salmonella | Cefotaxime or<br>Ceftriaxone              | Idem   |

Source : Nduwimana JMV, *Méningites associées au VIH/SIDA chez l'adulte au CHK : Aspects diagnostic, thérapeutique, et évolutif. A propos de 82 cas.*

## C. Treatment outcomes

A good evolution (recovering) of meningitis associated with HIV/AIDS depends on different factors such as precocity of diagnosis, treatment, prescription and respect of specific drugs and immunity state of the patient. The mean of the healing rate is 60% in all forms of meningitis.

**Mortality/Morbidity:** Mortality rates and morbidity vary by the etiology of meningitis and its values remain elevated. In 2005, in Malawi Robertson et al. (15) found a mortality rate of 35% in well treated *Cryptococcus* meningitis patients. Higher mortality rates correlate with poor mental status, high CSF opening pressure at presentation, positive India ink test, extra-CNS manifestations, and higher fungal burdens.

**Complications:**

- *Cryptococcus* meningitis may recur after treatment. Without maintenance therapy, 50-70% of patients relapse within 1 year. The rate decreases to 2-7% in patients treated with long-term fluconazole.
- CMV encephaloventriculitis also may recur. As for cryptococcal meningitis, relapse within 1 year is most likely in patients who do not receive maintenance therapy.

## **III. METHODS**

### **III.1. Study design**

The study design is a retrospective descriptive study covering a 6-year period from the 1<sup>st</sup> of January 2001 to 31<sup>st</sup> of December 2006.

### **III.2 Ethical issues**

Since we were doing a retrospective study, we were not able to consult the patients or their families to obtain their informed consent.

### **III.2. Area of the study**

It concerns all HIV/AIDS positive patients hospitalized in the Internal Medicine Department of the Butare University Teaching Hospital during the period of our study. CHUB is a referral hospital, specially for the southern region. It also contributes in the training of medical students.

### **III.3. Inclusion criteria**

We included all HIV/AIDS-positive patients who were hospitalized in the time from 01/01/2001 to 31/12/2006 because of meningitis

### **III.4 Methodology of data collection**

#### **III.4.1 Collected data**

Questionnaires filled with data from patients folders. The questionnaire contained:

- Socio-demographic data: age, sex, address, profession, matrimonial status.
- Clinical data:
  - Anamnesis: Past medical history, duration of symptoms
  - Physical examination: meningitis clinical signs, HIV/AIDS clinical manifestations
  - Laboratory findings: CSF results
  - Others:
    - Final diagnosis: these data were retrieved from the patient file.
    - Treatment
    - Outcome: categories were “healed”, “dead” and “unknown”. Information about sequelae were rare in the files.

#### **III.4.2 Data management**

Data were collected onto paper questionnaires and entered onto the computerized questionnaires driven by epi-data software. The final analysis was done with the help of SPSS (version 14.0). Please find the questionnaire in the annexes. As threshold for the statistical tests we used a p value of <0.05.

**III.5. Limitations**

- Some patients' files were incomplete and we lacked information on many items such as CD4 count, complications, since when the patient is living with HIV, past medical history and so on.
- Specific diagnosis of meningitis was sometimes not available because of lack of more specific diagnostic tests for bacterial (syphilitic), viral and parasitic meninges infections.



## IV. RESULTS

Between 2001 and 2006, in a total number of 495 hospitalized HIV-positive patients, 86 cases (17.37%) of meningitis have been recorded.

Table 6: Comparison of meningitis and other pathologies in HIV-positive patients in our study

| Pathology                | Number | Percentage |
|--------------------------|--------|------------|
| <b>Meningitis</b>        | 86     | 17.37%     |
| <b>Other pathologies</b> | 409    | 82.63%     |
| <b>Total</b>             | 495    | 100%       |

Table 7: Distribution of HIV patients hospitalized from 2001-2006


| Year                                   | 2001  | 2002  | 2003  | 2004  | 2005  | 2006  |
|--|-------|-------|-------|-------|-------|-------|
| <b>Number of HIV-positive patients</b> | 63    | 63    | 97    | 124   | 73    | 76    |
| <b>Number of meningitis</b>            | 13    | 14    | 17    | 14    | 14    | 13    |
| <b>Prevalence (%)</b>                  | 20.63 | 22.22 | 17.52 | 11.29 | 19.17 | 17.10 |

### IV.1 Description of the study population

Due to the inclusion criteria, all the 86 patients of our study had a co-infection of HIV and meningitis. Three types of meningitis including Cryptococcus, TB and Bacterial meningitis were observed. No case of viral, parasitic or candida meningitis was recorded over the period of study.

Table 8: Types of meningitis

|                    |              | Number of patients | Percent |
|--------------------|--------------|--------------------|---------|
| Type of meningitis | Cryptococcus | 55                 | 64.0    |
|                    | TB           | 21                 | 24.4    |
|                    | Bacterial    | 10                 | 11.6    |
|                    | Total        | 86                 | 100.0   |



Graph 1: types of meningitis observed

## IV.2 Socio-demographic profile of the study population

### IV.2.1 Origin

On a total number of 86 patients included in our study, 76 (88,4%) are from the southern province, 1 from the eastern province, 3 from the western province and 6 from Kigali City.

Table 9: Origin of the patients

|       | Number of patients | Percent |
|-------|--------------------|---------|
| south | 76                 | 88.4    |
| east  | 1                  | 1.2     |
| west  | 3                  | 3.5     |
| MVK   | 6                  | 7.0     |
| Total | 86                 | 100.0   |

### IV.2.2 Age of the patients

In our study 72 patients (83.7%) are less than 45 years old. The 26-45 age group is the most affected by HIV-meningitis co-infection with 70 patients (81.4%) and *Cryptococcus neoformans* was the most frequent cause of meningitis in the same group (61.4%). The difference is not statistically significant ( $p=0.696$ ). The mean age was 38.6 and ranging from 20 to 75. (Table 10)

Table 10: Distribution of HIV-meningitis co-infection by age group

|           | Type of meningitis |    |           | Total |
|-----------|--------------------|----|-----------|-------|
|           | Cryptococcus       | TB | Bacterial |       |
| Age <= 24 | 2                  | 0  | 0         | 2     |
| 25 - 29   | 6                  | 3  | 0         | 9     |
| 30 - 34   | 10                 | 5  | 5         | 20    |
| 35 - 39   | 13                 | 1  | 3         | 17    |
| 40 - 44   | 12                 | 7  | 1         | 20    |
| 45 - 49   | 4                  | 3  | 1         | 8     |
| 50 - 54   | 4                  | 0  | 0         | 4     |
| 55 - 59   | 2                  | 0  | 0         | 2     |
| 60 - 64   | 0                  | 1  | 0         | 1     |
| 70 - 74   | 0                  | 1  | 0         | 1     |
| 75+       | 1                  | 0  | 0         | 1     |
| Total     | 54                 | 21 | 10        | 85    |

#### IV.2.3 Sex

In 86 HIV-positive patients who developed meningitis 51 were female (59.3%) and 35 male (40.7%) with a male/female ratio of 0.68. Cryptococcus meningitis was the most prevalent type in both sexes. The difference is not statistically significant ( $p=0.405$ ).

Table 11: Distribution of HIV-meningitis co-infection by sex

|        |       |  | Type of Meningitis |       |           | Total  |
|--------|-------|--|--------------------|-------|-----------|--------|
|        |       |  | Cryptococcus       | TB    | Bacterial |        |
| Sex: F | Count |  | 34                 | 10    | 7         | 51     |
|        | %     |  | 66.7%              | 19.6% | 13.7%     | 100.0% |
| M      | Count |  | 21                 | 11    | 3         | 35     |
|        | %     |  | 60.0%              | 31.4% | 8.6%      | 100.0% |
| Total  | Count |  | 55                 | 21    | 10        | 86     |
|        | %     |  | 64.0%              | 24.4% | 11.6%     | 100.0% |

#### IV.2.4 Occupation

The majority of HIV-positive patients affected by meningitis were farmers (60), followed by state employees (24), and one private sector employee.

Table 12: Distribution of HIV-meningitis co-infection by occupation

|            |         |       | Type of meningitis |        |           | Total  |
|------------|---------|-------|--------------------|--------|-----------|--------|
|            |         |       | Crypto             | TB     | Bacterial |        |
| Profession | Farmer  | Count | 38                 | 15     | 7         | 60     |
|            |         | %     | 63.3%              | 25.0%  | 11.7%     | 100.0% |
|            | State   | Count | 16                 | 5      | 3         | 24     |
|            |         | %     | 66.7%              | 20.8%  | 12.5%     | 100.0% |
|            | Private | Count | 0                  | 1      | 0         | 1      |
|            |         | %     | .0%                | 100.0% | .0%       | 100.0% |
|            | Other   | Count | 1                  | 0      | 0         | 1      |
|            |         | %     | 100.0%             | .0%    | .0%       | 100.0% |
| Total      |         | Count | 55                 | 21     | 10        | 86     |
|            |         | %     | 64.0%              | 24.4%  | 11.6%     | 100.0% |

#### IV.2.5 Marital status

Table 13: Repartition of HIV-meningitis co-infection by marital status

|                 |           |       | Type of Meningitis |       |           | Total  |
|-----------------|-----------|-------|--------------------|-------|-----------|--------|
|                 |           |       | Cryptococcus       | TB    | Bacterial |        |
| Marital Status: | Single    | Count | 9                  | 3     | 0         | 12     |
|                 |           | %     | 75.0%              | 25.0% | .0%       | 100.0% |
|                 | Married   | Count | 21                 | 9     | 4         | 34     |
|                 |           | %     | 61.8%              | 26.5% | 11.8%     | 100.0% |
|                 | Separated | Count | 1                  | 1     | 0         | 2      |
|                 |           | %     | 50.0%              | 50.0% | .0%       | 100.0% |
|                 | Widow     | Count | 10                 | 3     | 2         | 15     |
|                 |           | %     | 66.7%              | 20.0% | 13.3%     | 100.0% |
| Total           |           | Count | 41                 | 16    | 6         | 63     |
|                 |           | %     | 65.1%              | 25.4% | 9.5%      | 100.0% |

## IV.2.6 Distribution of patients according on the period of study

Table 14: Distribution of patients by year of hospital stay

|            |       |  | Type of Meningitis |       |           | Total  |
|------------|-------|--|--------------------|-------|-----------|--------|
|            |       |  | Cryptococcus       | TB    | Bacterial |        |
| Year: 2001 | Count |  | 12                 | 0     | 1         | 13     |
|            | %     |  | 92.3%              | .0%   | 7.7%      | 100.0% |
| 2002       | Count |  | 8                  | 4     | 2         | 14     |
|            | %     |  | 57.1%              | 28.6% | 14.3%     | 100.0% |
| 2003       | Count |  | 11                 | 3     | 3         | 17     |
|            | %     |  | 64.7%              | 17.6% | 17.6%     | 100.0% |
| 2004       | Count |  | 7                  | 6     | 1         | 14     |
|            | %     |  | 50.0%              | 42.9% | 7.1%      | 100.0% |
| 2005       | Count |  | 9                  | 4     | 1         | 14     |
|            | %     |  | 64.3%              | 28.6% | 7.1%      | 100.0% |
| 2006       | Count |  | 7                  | 4     | 2         | 13     |
|            | %     |  | 53.8%              | 30.8% | 15.4%     | 100.0% |
| Total      | Count |  | 54                 | 21    | 10        | 85     |
|            | %     |  | 63.5%              | 24.7% | 11.8%     | 100.0% |

**p=0.478**

## IV.3 Past medical history and Clinical aspects

### IV.3.1 Past medical history

Among 86 patients with meningitis 20 (23%) had a history of tuberculosis, 6 (7%) a history of meningitis, 3 (3.5%) a history of pneumonia. Only one patient with Cryptococcus meningitis had a previous history of facial palsy. Past history of meningitis were more frequent in patients with Cryptococcus meningitis with a statistically significant difference ( $p=0.035$ ).

Table 15: Distribution of patients according to past morbid history and type of meningitis


|                       |   | Type of meningitis         |                  |                         | P value<br>(chi-Square) | Statistic<br>decision |
|-----------------------|---|----------------------------|------------------|-------------------------|-------------------------|-----------------------|
|                       |   | Cryptococcus<br>Meningitis | TB<br>Meningitis | Bacterial<br>Meningitis |                         |                       |
|                       |   | %                          | %                | %                       |                         |                       |
| Tuberculosis          | Y | 25.5                       | 23.8             | 10.0                    | 0.075                   | Not Significant       |
| Meningitis            | Y | 12.7                       | 9.5              | 10.0                    | 0.035                   | Significant           |
| Pneumonia             | Y | 3.6                        | 4.8              | 0.0                     | 0.088                   | Not Significant       |
| Others (facial palsy) | Y | 1.8                        | 0.0              | 0.0                     | 0.752                   | Not significant       |

### IV.3.2 Clinical signs of meningitis in HIV-positive patients

Headache ( $p=0.163$ ), high fever ( $p=0.961$ ), neck stiffness ( $p=0.005$ ), Kernig sign ( $p=0.181$ ) and vomiting ( $p=0.941$ ) are the most frequent signs in all types of meningitis seen in our study. There is no statistically significant difference of clinical signs between the different types of meningitis except for neck stiffness which is more associated with bacterial meningitis than others ( $p=0.05$ ).

Table 16: Distribution of patients according to clinical signs and types of meningitis

|                            |   | Type of meningitis      |               |                      | P value (chi-Square) | Statistic decision |
|----------------------------|---|-------------------------|---------------|----------------------|----------------------|--------------------|
|                            |   | Cryptococcus meningitis | TB meningitis | Bacterial meningitis |                      |                    |
|                            |   | %                       | %             | %                    |                      |                    |
| Headache                   | Y | 85.5                    | 81.0          | 60.0                 | 0.163                | Not significant    |
| Fever                      | Y | 65.5                    | 66.7          | 70.0                 | 0.961                | Not significant    |
| Neck stiffness             | Y | 38.2                    | 71.4          | 80.0                 | 0.005                | Significant        |
| Kernig sign                | Y | 16.4                    | 28.6          | 40.0                 | 0.181                | Not significant    |
| Conscious troubles         | Y | 34.5                    | 23.8          | 30.0                 | 0.662                | Not significant    |
| Photophobia                | Y | 3.6                     | 0.0           | 0.0                  | 0.739                | Not significant    |
| Motor and sensory deficits | Y | 5.5                     | 0.0           | 0.0                  | 0.416                | Not significant    |
| Vomiting                   | Y | 45.5                    | 42.9          | 40.0                 | 0.941                | Not significant    |



Graph 2: Neck stiffness in HIV-positive patients affected by meningitis

### IV.3.3 Clinical manifestation of HIV/AIDS

Dermatosis, condylomas and vaginal candidiasis have been only seen in patients with a cryptococcus meningitis co-infection. Meanwhile progressive wasting is more associated with tuberculous meningitis with a statistically significant difference ( $p=0.047$ ). (Table 17).

Table 17: Distribution of patients according to clinical manifestation of HIV and type of meningitis

|   |   | Type of meningitis      |               |                      | P value<br>(chi-Square) | Statistic decision |
|---|---|-------------------------|---------------|----------------------|-------------------------|--------------------|
|   |   | Cryptococcus meningitis | TB meningitis | Bacterial meningitis |                         |                    |
|   |   | %                       | %             | %                    |                         |                    |
| Progressive wasting                               | Y | 14.5                    | 33.3          | 0.0                  | 0.047                   | Significant        |
| Long lasting fever                                | Y | 12.7                    | 9.5           | 10.0                 | 0.913                   | Not significant    |
| Chronic diarrhoea                                 | Y | 1.8                     | 4.8           | 0.0                  | 0.654                   | Not Significant    |
| Chronic cough                                     | Y | 10.9                    | 4.8           | 10.0                 | 0.709                   | Not significant    |
| Oral Candidosis                                   | Y | 30.9                    | 33.3          | 10.0                 | 0.361                   | Not significant    |
| Zona  | Y | 3.6                     | 4.8           | 0.0                  | 0.792                   | Not significant    |
| Other (condyloma, dermatosis, vaginal candidosis) | Y | 5.4                     | 0.0           | 0.0                  | 0.941                   | Not significant    |

### IV.3.4 Distribution of patients according to type of meningitis and CSF biochemical parameters

#### a. CSF macroscopic aspect

Table 18: Distribution according to the macroscopic aspects of CSF

|                    |               |       | Type of meningitis |       |           | Total  |
|--------------------|---------------|-------|--------------------|-------|-----------|--------|
|                    |               |       | Cryptococcus       | TB    | Bacterial |        |
| Macroscopic aspect | Clear         | Count | 49                 | 18    | 0         | 67     |
|                    |               | %     | 73.1%              | 26.9% | .0%       | 100.0% |
|                    | Xanthochromic | Count | 2                  | 0     | 1         | 3      |
|                    |               | %     | 66.7%              | .0%   | 33.3%     | 100.0% |
|                    | Purulent      | Count | 1                  | 1     | 9         | 11     |
|                    |               | %     | 9.1%               | 9.1%  | 81.8%     | 100.0% |
|                    | Hematic       | Count | 1                  | 1     | 0         | 2      |
|                    |               | %     | 50.0%              | 50.0% | .0%       | 100.0% |
| Total              | Count         | 53    | 20                 | 10    | 83        |        |
|                    | %             | 63.9% | 24.1%              | 12.0% | 100.0%    |        |

P=0.000

### b. CSF glucose and protein

CSF biochemical parameters were measured in 73 patients. Among them 54 had hypoglycorrhachia (59.3% with *Cryptococcus meningitis*), 15 had normal CSF glucose level and 4 had hyperglycorrhachia. All the patients with bacterial meningitis had diminished CSF glucose. The difference is not statistically significant ( $p=0.351$ ). (Table 19). The CSF protein level is higher in bacterial and tuberculous meningitis ( $p=0.001$  using Kruskal Wallis test)

Table 19: Distribution of patients according to CSF glucose and type of meningitis

|                     |         |       | Type of meningitis |       |           | Total  |
|---------------------|---------|-------|--------------------|-------|-----------|--------|
|                     |         |       | Cryptococcus       | TB    | Bacterial |        |
| CSF Glucose (mg/dl) | <= 45   | Count | 32                 | 15    | 7         | 54     |
|                     |         | %     | 59.3%              | 27.8% | 13.0%     | 100.0% |
|                     | 46 - 80 | Count | 12                 | 3     | 0         | 15     |
|                     |         | %     | 80.0%              | 20.0% | .0%       | 100.0% |
|                     | 81+     | Count | 2                  | 2     | 0         | 4      |
|                     |         | %     | 50.0%              | 50.0% | .0%       | 100.0% |
| Total               |         | Count | 46                 | 20    | 7         | 73     |
|                     |         | %     | 63.0%              | 27.4% | 9.6%      | 100.0% |

Table 20: Distribution of patients according to LCR proteins and type of meningitis

|              | Type of meningitis      | N  | Mean Rank |
|--------------|-------------------------|----|-----------|
| LCR Proteins | Cryptococcus meningitis | 46 | 27,80     |
|              | TB                      | 20 | 52,05     |
|              | Bacterial               | 7  | 54,43     |
|              | Total                   | 73 |           |

### c. CSF white blood cells

CSF WBC count shows hypercytosis with neutrophilic predominance, normal WBC count in *Cryptococcus meningitis*. A moderate hypercytosis is noticed in tuberculous meningitis ( $p=0.002$ )

Table 21: Distribution of patients by CSF WBC count and type of meningitis

|            |         |       | Type of meningitis |       |           | Total  |
|------------|---------|-------|--------------------|-------|-----------|--------|
|            |         |       | Cryptococcus       | TB    | Bacterial |        |
| Leucocytes | <= 5    | Count | 6                  | 1     | 0         | 7      |
|            |         | %     | 85.7%              | 14.3% | .0%       | 100.0% |
|            | 6 - 250 | Count | 25                 | 8     | 2         | 35     |
|            |         | %     | 71.4%              | 22.9% | 5.7%      | 100.0% |
|            | 251+    | Count | 11                 | 10    | 8         | 29     |
|            |         | %     | 37.9%              | 34.5% | 27.6%     | 100.0% |
| Total      |         | Count | 42                 | 19    | 10        | 71     |
|            |         | %     | 59.2%              | 26.8% | 14.1%     | 100.0% |



#### IV.4 Outcome

Among 55 patients with Cryptococcus meningitis 43.6% recovered and 40% died for the rest we did not have the information on whether they recovered or not. 28.6% of TB meningitis patients died and 47.6% recovered. For bacterial meningitis patients, 60% died and 30% recovered. The difference is not statistically significant with  $p=0.550$  (Table 19)

Table 22: Outcome after treatment according to the type of meningitis

|         |       | Type of Meningitis |        |           | Total  |
|---------|-------|--------------------|--------|-----------|--------|
|         |       | Cryptococcus       | TB     | Bacterial |        |
| Heal    | Count | 24                 | 10     | 3         | 37     |
|         | %     | 43.6%              | 47.6%  | 30.0%     | 43.0%  |
| Death   | Count | 22                 | 6      | 6         | 34     |
|         | %     | 40.0%              | 28.6%  | 60.0%     | 39.5%  |
| Unknown | Count | 9                  | 5      | 1         | 15     |
|         | %     | 16.4%              | 23.8%  | 10.0%     | 17.4%  |
| Total   | Count | 55                 | 21     | 10        | 86     |
|         | %     | 100.0%             | 100.0% | 100.0%    | 100.0% |

#### IV.5 Duration of stay in hospital

The mean hospitalization duration was 15.6 days in Cryptococcus meningitis, 28.25 days in TB meningitis, and 12.0 days in bacterial meningitis. The difference of hospitalization duration is not statistically significant ( $p=0.140$ ).Table (20)

Table 23: Duration of hospitalization according to the type of meningitis

|         |         | Type of meningitis |       |           | Total |
|---------|---------|--------------------|-------|-----------|-------|
|         |         | Cryptococcus       | TB    | Bacterial |       |
| Days    | <= 14   | 31                 | 6     | 7         | 44    |
|         | 15 - 30 | 17                 | 10    | 2         | 29    |
|         | 31+     | 4                  | 4     | 1         | 9     |
| Total   |         | 52                 | 20    | 10        | 82    |
| Mean    |         | 15.67              | 28.25 | 12.00     |       |
| Minimum |         | 1                  | 3     | 1         |       |
| Maximum |         | 110                | 120   | 32        |       |

## IV.6 Prognostic

There is an association between duration of treatment and the outcome. Among 35 patients hospitalized less than 14 days, 25 died and among 32 hospitalized more than 15 days 7 patients died. The difference is statistically significant ( $p=0.001$ ).

Table 24: Outcome according to the duration of treatment

|                       |         | Outcome |       | Total |
|-----------------------|---------|---------|-------|-------|
|                       |         | heal    | death |       |
| Duration of treatment | <= 14   | 10      | 25    | 35    |
|                       | 15 - 30 | 19      | 6     | 25    |
|                       | 31+     | 4       | 3     | 7     |
| Total                 |         | 33      | 34    | 67    |

## **V. DISCUSSIONS AND COMMENTS**

### **V.1 General view**

The internal medicine service of CHUB is among the sites receiving the highest number of HIV-positive patients in Rwanda. In our study 495 HIV-positive patients have been hospitalized in the same service between 2001 and 2006. Among them 86 (17.3%) were hospitalized for meningitis with lymphocytic meningitis predominance ( $p=0.000$ ). Since 2003, the co-infection rate is slightly decreasing probably due to a better management of HIV-positive patients (free antiretroviral drugs available for eligible patients).

In France 2004, Dromer et al. (4), demonstrated a 46% decreased incidence of *Cryptococcus* infection after the introduction of HAART.

### **V.2 Socio-demographic profile of study population**

#### **V.2.1 Origin of the patients**

The majority of our patients (88.4%) are from the southern region of Rwanda. This is due to the geographic situation of CHUB, most of its patients coming from south.

#### **V.2.2 Types of meningitis according to sex and age**

In our study, 51 women and 35 men have been recorded (sex ratio men/women: 0,7). This female predominance is not statistically significant ( $p=0.405$ ). The mean age was 38.6, ranging from 20 to 75, the most affected age group was 26-45.

In Rwanda (CHUK), in 1992, BOGAERTS et al. (8) found a male predominance with men/women sex ratio of 1.5 for *Cryptococcus* meningitis, 1.17 for TB meningitis, with a mean age of 36.3. In Burundi (Bujumbura), in 1990, LAROCHE, et al. (14) found a male/female ratio 1.7 with a mean age of 37, ranging from 23 to 66 in patients with *Cryptococcus* meningitis.

The female predominance mainly in *Cryptococcus* meningitis might be due to the fact that Rwandese women and girls are constantly in agricultural work and in other activities and thus exposed to *Cryptococcus* germ which is staying in such environment.

### **V.3 Etiologies of meningitis in HIV-positive patients**

In 86 cases of HIV-meningitis, 3 etiologies of meningitis were observed: *Cryptococcus* meningitis (64%), TB meningitis (24.4%) and bacterial meningitis (11.6%). In general *Cryptococcus* and TB are very common in HIV-positive patients. The high prevalence of *Cryptococcus* meningitis could be related to the high prevalence of HIV/AIDS (3%) in our country which contributes to the proliferation of this causal germ in nature. As discussed already in chapter III.5 (Limitations) it is likely that not all etiologies were diagnosed. This can be explained by the lack of the diagnosis tests for viral meningitis, syphilitic meningitis and parasitic infections (e.g. toxoplasmosis). (13)

The prevalence of TB meningitis could also be related to the high prevalence of active tuberculosis at another site in HIV/AIDS patients. In Ivory Coast, LUCAS SB et al. (11), in 1993, observed 20% of TB meningitis within HIV-positive patients with tuberculosis.

In 1994, in Malawi, MAHER et al. (12) and in 1992 DE COCK et al. (3) in South Africa, documented *Cryptococcus* and TB meningitis as the main etiologies of HIV-meningitis association. In Rwanda (CHUK) in 2001 KARASI (10) found a cryptococcal predominance in 2160 cases of meningitis.

## **V.4 Clinical aspects**

### **V.4.1. Clinical signs**

Headache, fever, neck stiffness, vomiting, was the most frequent clinical manifestations of meningitis in HIV-positive patients in our study.

Our results are also supported by a study done by Chuck and Sande (2), in 1989 where the patients infected with HIV cryptococcal meningitis typically present with fever, headache, nausea and vomiting, and cognitive dysfunction. Meningeal signs and photophobia are less common than in patients who are HIV negative; focal findings and seizures may be seen but are uncommon. Although the onset of disease can be acute, it is more often chronic or insidious.

Among the clinical signs of HIV infection, progressive wasting ( $p=0.047$ ), oral candidosis ( $p=0.361$ ) and long lasting fever (0.913) were the most frequent observed manifestations in our study population.

This can be explained by the fact that *Cryptococcus* meningitis as well as progressive wasting, oral candidosis and long lasting fever onset occur at later stages of HIV/AIDS infection.

Similarly in 2002, NDUWIMANA (7), observed in CHUK that in HIV patients with meningitis, clinical manifestations of AIDS were led by progressive wasting ( $p=0.0000$ ), long lasting fever ( $p=0.0004$ ), chronic cough ( $p=0.0006$ ) and oral candidosis ( $p=0.003$ ).

### **V.4.2 Past medical history**

Among 86 patients in our study, 20 (23.2%) had a history of Tuberculosis ( $p=0.075$ ). This can be explained by the fact that HIV-infected patients are more likely predisposed to tuberculosis at any anatomical site. In South Africa ELI SILBER et al. (5) documented a history of tuberculosis in 55% patients with HIV-meningitis association.

In our study, 6 (6.97%) patients had a history of meningitis. Unfortunately there was no further information about the type and circumstances of the previous meningitis. Recurrent meningitis is very common in cryptococcal meningitis.

## **V.5 Para clinic aspects**

Of a total number of 66 patients with lymphocytic meningitis more than 71.21% had low CSF glucose level ( $<45\text{mg/dl}$ ) and high CSF protein ( $>45\text{mg/dl}$ ). Normal values were mainly observed in *Cryptococcus* meningitis patients. All patients with bacterial meningitis had an association of low CSF glucose and high CSF protein, as it was expected.

In Zimbabwe, HAKIM et al. (9) found 10% of normal CSF within cryptococcal meningitis patients. 90% had an association of hypercytosis, low CSF glucose level, and high CSF protein level.

In South Africa, SILBER et al. (5) documented 33% of normal CSF results mainly within patients affected by cryptococcus meningitis while 67% had classic CSF abnormalities. Normal CSF findings have been also noticed by ZUGER et al. (18) in cryptococcal meningitis.

## **V.6 Outcome in the hospital**

Among 86 patients of our study a clinical improvement have been noticed for 43.0%. The difference between three types of meningitis is not statistically significant ( $p=0.550$ ). This low number of clinical improvement can be explained in some cases by low income for some patients. This lack of possibilities to buy themselves the indicated drugs creates irregularities in meningitis management. In South Africa BERGMAN and KARSTAEDT (1) documented a clinical improvement of 50% while ZUGER (18) in America found a clinical improvement in more than 60% of his patients. In one study from Malawi, availability of fluconazole has decreased the mortality of cryptococcal meningitis from 100% to 35% (Robertson et al, 2005).

The number of deaths was 34 (39.5%) among 86 patients of our study, among them 64.7% are from *Cryptococcus meningitis*. The high mortality rate (40%) of cryptococcal meningitis can be explained by poor prognosis of this type of meningitis and the severe HIV/AIDS immuno-depression. Particularly the lack and the elevated cost of anti fungal drugs have probably contributed in increasing the cryptococcal meningitis related mortality.

In Zimbabwe, HAKIM et al. (9) found a mortality rate of 68% in HIV-positive patients with an acute meningitis co-infection. NDUWIMANA in 2002 in CHUK (7), observed that in patients with meningitis 59,5% of deaths were due to *Cryptococcus meningitis*

Compared with patients who have “conventional” bacterial meningitis, patients with lymphocytic meningitis typically have stayed in the hospital for a longer time. This can be explained by the fact that these types of meningitis are more likely to undergo a chronic stage.

## **V.7. Prognostic factors**

There is an association between the duration of stay in hospital and the outcome. If you survive the first 14 days, the chances get better to recover. The lack of some information limited our further investigations in factors that affect the outcome after treatment.

In 1997, a study by van der Horst and colleagues (17), found in HIV-positive patients with cryptococcal meningitis managed with Amphotericin B and Floconazole that mortality was 5.5% in the first 2 weeks of treatment and 3.9% in the subsequent 8 weeks.

## VI. Conclusions and recommendations

### VI.1. Conclusions

#### a) Epidemiological aspects

- Meningitis remains among the most common HIV/AIDS opportunistic diseases in internal medicine department of CHUB (17.37%).
- The most affected age group is the one from 26-45, note that this group is the economically active group.

#### b) Etiologic view

We observed a high prevalence of cryptococcal and tuberculous meningitis in HIV-infected patients:

- In our study (among HIV-infected patients) *Cryptococcus neoformans* was the most common causal germ of meningitis (64.0%).
- Tuberculous meningitis is also a common causal germ of meningitis in patients infected by HIV (24.4%).

#### c) Clinical aspects

- Headache, high fever, neck stiffness, Kernig sign and vomiting are the most frequent signs in all types of meningitis seen in our study.
- Neck stiffness is more associated with tuberculous and Bacterial meningitis ( $p=0.005$ )

#### d) Para clinic aspects

- The laboratory diagnostic of *Cryptococcus* meningitis is easier and highly specific using Indian ink ( $p=0.000$ ).
- Because CSF smear and culture are insensitive, diagnosis of tuberculous meningitis is often presumptive. It is then based on compatible clinical findings and CSF profile, risks for tuberculosis. Only in a few patients active tuberculosis can be identified at another anatomical site.
- The diagnostic of bacterial meningitis is mainly based on bacteriological and biological findings. It is easily established in presence of turbid CSF, hypercytosis (neutrophilic predominance), low CSF glucose level and high CSF protein level.
- According to our findings the CSF protein level is more significant than CSF glucose level to differentiate between on one hand cryptococcal meningitis and on other hand tuberculous and bacterial meningitis ( $p=0.001$ ).

#### e) Management and outcome

- Management of *Cryptococcus* meningitis using Amphotericin B is efficient, but its elevated costs have limited its accessibility and this leads to an increased mortality due to this type of meningitis. Furthermore severe side effects influence the duration of the treatment.
- The national protocol for management of tuberculosis is valid in HIV-positive patients with TB meningitis.
- Chances to recover are increased after the first 2 weeks of treatment

## VI.2 Recommendations

Our study is a modest contribution about the HIV-meningitis association in the department of Internal Medicine of CHUB. Nevertheless some recommendations are expressed to:

The Ministry of Health:

- Considered the fact that anti fungal drugs are hardly affordable to our population, it is necessary to supply all referral and district hospital with Amphotericine B and Fluconazole to be freely given to all the patients with Cryptococcus meningitis.
- Provide hospitals with necessary materials to perform Indian ink and cryptococcal antigen tests for an early diagnosis of Cryptococcus meningitis.

The physicians:

- Elaborate more precise and systematic patients' folders, with well organized data to facilitate future studies
- Do systematically lumbar puncture and measure CSF outlet pressure, essentially focus on Ink Indian in HIV-positive patients suspicious of meningitis.
- Establish a consistent system for follow up of those patients to manage further complications of meningitis.

The NUR faculty of medicine:

- Future research should address the coinfection HIV and meningitis and the socio-economic impact of this condition (on the patient and his family as well as on society). Further studies on its prevention would be desirable.
- A prospective design of this future study would be desirable.

## REFERENCES

1. BERGMAN and A.S. KARSTAED. The spectrum of meningitis in a population with high prevalence of HIV disease. *QJ Med* 1996; 89:499-504
2. Chuck SL, Sande MA. Infections with *Cryptococcus neoformans* in the acquired immunodeficiency syndrome. *N Engl J Med* 1989;321:794–799.
3. DE COCK KM, SORO B, COULIBARY IM, LUCAS SB. Tuberculosis and HIV infection in sub-Saharan Africa *J Am Med Assoc* 1992; 268:1581-1587.
4. Dromer F, Mathoulin-Pelissier S, Fontanet A, et al. Epidemiology of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre- and post-HAART eras. *AIDS* 2004;18:555–562.
5. ELI SILBER, PAMELA SONNENBERG, KEVIN C.HO, HENDRIK J.KOORNHOF, SHAUN EINTRACHT, LYNN MORRIS et al. Meningitis in a community with a high prevalence of tuberculosis and HIV infection.
6. Hammer and Collony, Viral aseptic meningitis in the limited states: clinical features, viral etiologies and differential diagnosis
7. Nduwimana JMV, Méningites associées au VIH/SIDA chez l'adulte au CHK : Aspects diagnostic, thérapeutique, et évolutif. A propos de 82 cas.
8. J. BOGAERTS, D.ROUVROY, H.TAELAMAN, A. KAGAME, M.A. AZIZ, D. SWINNE et al. AIDS associated cryptococcal meningitis in Rwanda (1983-1992) :Epidemiologic and diagnosis features. *Journal of infection* 1999; 39:32-3
9. James G. HAKIM , INNOCENT T.GONGAIZDO, ROBERT S.HEYDERMAN, JENS MIELKE, EBBAH MUSHANGI, ALBERT TAZIWA et al. Impact of HIV infection on meningitis in Harare, Zimbabwe: a prospective study of 406 predominantly adults patients. *AIDS* 2000; 14:1401-1407. *Journal of the Neurological sciences* 1999; 162:20-26
10. KARASI J.C. Les meningites bacteriennes : étude microbiologique. A propos de 2160 cas. Mémoire de la faculté de Médecine. 2001
11. LUCAS SB, HOUNNOU A, PEACOCK C et al. The mortality and pathology of HIV infection in a West Africa city. *AIDS* 1993; 7:1569-1579
12. MAHER D, MWANDUMBA H. Cryptococcal meningitis in Lilongwe and Blantyre. *Malawi J infect* 1994; 28:59-64.
13. Marra, Christina M, Infections of the central nervous system in patients infected with HIV. *Continuum Neurology*, 2006; 12(2): 111-132
14. R. LAROCHE, et al., *Cryptococcus* in Bujumbura Burundi: apropos of 80 cases observed in 42 months, *Bull. Soc. Pathol. Exot. Fil.* 83 159 1990
15. Robertson K, Kopnisky K, Mielke J, et al. Assessment of neuroAIDS in Africa. *J Neurovirol* 2005; 11:7-16
16. UNAIDS, AIDS epidemic update December 2006
17. Van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study and AIDS Clinical Trials Group. *N Engl J Med* 1997;337:15–21.
18. ZUGER A, LOUIS HOLZMAN RS SIMBERKOFF MS, RAHAL JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. *Ann Int Med* 1986; 104:234-240



**ANNEXES**